Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Phytomedicines are potential immunity-boosting components with effective anticystic properties, minimal side effects, and biomedical applications, making them valuable for combating various diseases. India is renowned globally for Ayurveda, an ancient treatment methodology known for its holistic approach in identifying the root cause of diseases. Tulsi () is a common household medicine in India. While essential oils from plants like Tulsi have long been recognized for their medicinal properties, there is a gap in understanding their potential in synthesizing gold nanoparticles (AuNPs) and their efficacy against breast carcinoma, particularly in the context of immunosuppressive conditions. We investigated the potential application of essential oils isolated from in the synthesis of AuNPs and their efficacy against MCF-7 breast carcinoma. Gas chromatography-mass spectroscopy identified compounds with potential anticancer effects against breast cancer cells. Synthesised AuNPs displayed high hemocompatibility and antimicrobial activity against nosocomial , , , and strains. Os-AuNPs induced chromosomal instability and mitotic arrest in the G2/M cell cycle phase. Subsequent fluorescence and cell cytometry studies demonstrated the systemic release of ROS, depolarisation of mitochondrial membrane potential, and production of apoptotic bodies. DNA damage and comet assays confirmed the anticancer potential of synthesised AuNPs. This study illuminates the potential of -derived AuNPs in breast carcinoma treatment, paving the way for future AuNP-based therapies in biomedicine.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367626PMC
http://dx.doi.org/10.1039/d4ra04807eDOI Listing

Publication Analysis

Top Keywords

breast carcinoma
16
gold nanoparticles
8
mcf-7 breast
8
essential oils
8
aunps efficacy
8
synthesised aunps
8
potential
7
breast
5
aunps
5
amelioration gold
4

Similar Publications

Background: Breast-conserving surgery (BCS) is the primary surgical approach for patients with breast cancer. The accurate determination of surgical margins during BCS is critical for patient prognosis; however, time constraints and limitations in current pathological techniques often prevent pathologists from performing this assessment intraoperatively. The inability to reliably assess margins during surgery can lead to incomplete tumor removal and the need for additional surgeries.

View Article and Find Full Text PDF

Background: Select patients with metastatic clear-cell renal-cell carcinoma can be treated without systemic therapy, yet few studies have explored this population. We investigated the efficacy of metastasis-directed therapy without systemic therapy in oligometastatic clear-cell renal-cell carincoma.

Methods: This investigator-initiated single-arm, phase 2 trial enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, histologically confirmed clear-cell renal-cell carcinoma, and one to five metastases.

View Article and Find Full Text PDF

Background: There is a demand for population level research on the potential genetic-basis of mesothelioma (e.g. BRCA1-associated protein-1 [BAP1]) independent of other risk factors, such as amphibole asbestos exposure.

View Article and Find Full Text PDF

PET/CT in breast cancer.

Rev Esp Med Nucl Imagen Mol (Engl Ed)

September 2025

Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Madrid, Spain; Grupo de Trabajo de Oncología de la SEMNIM, Spain.

Breast cancer is one of the most prevalent neoplasms worldwide, with molecular subtypes that influence prognosis and therapeutic strategies. PET/CT with different radiopharmaceuticals has revolutionized diagnosis, staging, and treatment monitoring. [F]-Fluorodeoxyglucose remains the most widely used radiotracer, but it has limitations in certain subtypes, such as invasive lobular carcinoma, where 16α-[F] fluoro-17β-estradiol and [Ga]-FAPI (fibroblast activation protein inhibitors) have demonstrated greater utility.

View Article and Find Full Text PDF

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), such as abemaciclib and ribociclib, have recently been incorporated as adjuvant strategy in combination with endocrine therapy (ET) for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer at higher risk of recurrence. However, despite a significant reduction in recurrence rates, a subset of patients still experiences distant metastatic spreading, with nearly 10% recurring during or shortly after adjuvant CDK4/6i completion, as observed in pivotal trials. To date, only one small retrospective study has described this emerging population while ongoing trials are not specifically addressing this scenario, leaving both the efficacy of postrelapse treatments and the biological background largely unknown.

View Article and Find Full Text PDF